Ligand Net Interest Income from 2010 to 2026
| LGND Stock | USD 191.69 6.64 3.35% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 468 K | Current Value 3 M | Quarterly Volatility 2.8 M |
Check Ligand Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 42.6 M, Interest Expense of 3.3 M or Total Revenue of 102.9 M, as well as many indicators such as Price To Sales Ratio of 9.27, Dividend Yield of 0.0558 or PTB Ratio of 2.02. Ligand financial statements analysis is a perfect complement when working with Ligand Pharmaceuticals Valuation or Volatility modules.
Ligand | Net Interest Income | Build AI portfolio with Ligand Stock |
Analyzing Ligand Pharmaceuticals's Net Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Interest Income has evolved provides context for assessing Ligand Pharmaceuticals's current valuation and future prospects.
Latest Ligand Pharmaceuticals' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Ligand Pharmaceuticals Incorporated over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Ligand Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ligand Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Ligand Net Interest Income Regression Statistics
| Arithmetic Mean | (8,997,004) | |
| Geometric Mean | 8,791,394 | |
| Coefficient Of Variation | (120.49) | |
| Mean Deviation | 8,239,760 | |
| Median | (12,178,000) | |
| Standard Deviation | 10,840,808 | |
| Sample Variance | 117.5T | |
| Range | 40.6M | |
| R-Value | 0.56 | |
| Mean Square Error | 86.6T | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | 1,193,029 | |
| Total Sum of Squares | 1880.4T |
Ligand Net Interest Income History
About Ligand Pharmaceuticals Financial Statements
Ligand Pharmaceuticals stakeholders use historical fundamental indicators, such as Ligand Pharmaceuticals' Net Interest Income, to determine how well the company is positioned to perform in the future. Although Ligand Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ligand Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ligand Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ligand Pharmaceuticals Incorporated. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 5.8 M | 6.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out the analysis of Ligand Pharmaceuticals Correlation against competitors. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Biotechnology sector continue expanding? Could Ligand diversify its offerings? Factors like these will boost the valuation of Ligand Pharmaceuticals. Expected growth trajectory for Ligand significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ligand Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.032 | Earnings Share 2.19 | Revenue Per Share | Quarterly Revenue Growth 1.228 | Return On Assets |
Understanding Ligand Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Ligand's accounting equity. The concept of intrinsic value - what Ligand Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ligand Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Ligand Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ligand Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ligand Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.